Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Plasma Proinflammatory Cytokines Are Markers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis.

Kumar NP, Moideen K, Banurekha VV, Nair D, Babu S.

Open Forum Infect Dis. 2019 May 31;6(7):ofz257. doi: 10.1093/ofid/ofz257. eCollection 2019 Jul.

2.

Altered circulating levels of B cell growth factors and their modulation upon anti-tuberculosis treatment in pulmonary tuberculosis and tuberculous lymphadenitis.

Kathamuthu GR, Moideen K, Banurekha VV, Nair D, Sridhar R, Baskaran D, Babu S.

PLoS One. 2018 Nov 14;13(11):e0207404. doi: 10.1371/journal.pone.0207404. eCollection 2018.

3.

Altered Systemic Adipokine Levels in Pulmonary Tuberculosis and Changes following Treatment.

Moideen K, Kumar NP, Nair D, Banurekha VV, Babu S.

Am J Trop Med Hyg. 2018 Oct;99(4):875-880. doi: 10.4269/ajtmh.18-0206.

4.

Modulation of Th1/Tc1 and Th17/Tc17 responses in pulmonary tuberculosis by IL-20 subfamily of cytokines.

Kumar NP, Moideen K, Banurekha VV, Nair D, Babu S.

Cytokine. 2018 Aug;108:190-196. doi: 10.1016/j.cyto.2018.04.005. Epub 2018 Apr 21.

5.

Heightened Systemic Levels of Neutrophil and Eosinophil Granular Proteins in Pulmonary Tuberculosis and Reversal following Treatment.

Moideen K, Kumar NP, Nair D, Banurekha VV, Bethunaickan R, Babu S.

Infect Immun. 2018 May 22;86(6). pii: e00008-18. doi: 10.1128/IAI.00008-18. Print 2018 Jun.

6.

Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.

Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D.

Lancet Respir Med. 2018 Apr;6(4):265-275. doi: 10.1016/S2213-2600(18)30078-X. Erratum in: Lancet Respir Med. 2018 Apr 18;:.

PMID:
29595509
7.

Modulation of iron status biomarkers in tuberculosis-diabetes co-morbidity.

Kumar NP, Banurekha VV, Nair D, Dolla C, Kumaran P, Babu S.

Tuberculosis (Edinb). 2018 Jan;108:127-135. doi: 10.1016/j.tube.2017.11.011. Epub 2017 Nov 24.

8.

Diminished plasma levels of common γ-chain cytokines in pulmonary tuberculosis and reversal following treatment.

Kumar NP, Banurekha VV, Nair D, Babu S.

PLoS One. 2017 Apr 27;12(4):e0176495. doi: 10.1371/journal.pone.0176495. eCollection 2017.

9.

Tuberculous Lymphadenitis Is Associated with Enhanced Baseline and Antigen-Specific Induction of Type 1 and Type 17 Cytokines and Reduced Interleukin-1β (IL-1β) and IL-18 at the Site of Infection.

Kathamuthu GR, Moideen K, Baskaran D, Banurekha VV, Nair D, Sekar G, Sridhar R, Vidyajayanthi B, Gajendraraj G, Parandhaman DK, Srinivasan A, Babu S.

Clin Vaccine Immunol. 2017 May 5;24(5). pii: e00045-17. doi: 10.1128/CVI.00045-17. Print 2017 May.

10.

Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.

Ramachandran G, Kumar AK, Kannan T, Bhavani PK, Kumar SR, Gangadevi NP, Banurekha VV, Sudha V, Venkatesh S, Ravichandran N, Kalpana S, Mathevan G, Sanjeeva GN, Agarwal D, Swaminathan S.

Pediatr Infect Dis J. 2016 May;35(5):530-4. doi: 10.1097/INF.0000000000001069.

PMID:
26825153
11.

Type 2 diabetes mellitus coincident with pulmonary or latent tuberculosis results in modulation of adipocytokines.

Pavan Kumar N, Nair D, Banurekha VV, Dolla C, Kumaran P, Sridhar R, Babu S.

Cytokine. 2016 Mar;79:74-81. doi: 10.1016/j.cyto.2015.12.026. Epub 2016 Jan 6.

12.

Circulating Angiogenic Factors as Biomarkers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis.

Kumar NP, Banurekha VV, Nair D, Babu S.

PLoS One. 2016 Jan 4;11(1):e0146318. doi: 10.1371/journal.pone.0146318. eCollection 2016.

13.

Modulation of pro- and anti-inflammatory cytokines in active and latent tuberculosis by coexistent Strongyloides stercoralis infection.

George PJ, Pavan Kumar N, Jaganathan J, Dolla C, Kumaran P, Nair D, Banurekha VV, Shen K, Nutman TB, Babu S.

Tuberculosis (Edinb). 2015 Dec;95(6):822-828. doi: 10.1016/j.tube.2015.09.009. Epub 2015 Oct 8.

14.

IL-27 and TGFβ mediated expansion of Th1 and adaptive regulatory T cells expressing IL-10 correlates with bacterial burden and disease severity in pulmonary tuberculosis.

Kumar NP, Moideen K, Banurekha VV, Nair D, Sridhar R, Nutman TB, Babu S.

Immun Inflamm Dis. 2015 Sep;3(3):289-99. doi: 10.1002/iid3.68. Epub 2015 Jun 18.

15.

Type 2 diabetes - Tuberculosis co-morbidity is associated with diminished circulating levels of IL-20 subfamily of cytokines.

Kumar NP, Banurekha VV, Nair D, Kumaran P, Dolla CK, Babu S.

Tuberculosis (Edinb). 2015 Dec;95(6):707-712. doi: 10.1016/j.tube.2015.06.004. Epub 2015 Aug 28.

16.

Heme Oxygenase-1 Regulation of Matrix Metalloproteinase-1 Expression Underlies Distinct Disease Profiles in Tuberculosis.

Andrade BB, Pavan Kumar N, Amaral EP, Riteau N, Mayer-Barber KD, Tosh KW, Maier N, Conceição EL, Kubler A, Sridhar R, Banurekha VV, Jawahar MS, Barbosa T, Manganiello VC, Moss J, Fontana JR, Marciano BE, Sampaio EP, Olivier KN, Holland SM, Jackson SH, Moayeri M, Leppla S, Sereti I, Barber DL, Nutman TB, Babu S, Sher A.

J Immunol. 2015 Sep 15;195(6):2763-73. doi: 10.4049/jimmunol.1500942. Epub 2015 Aug 12.

17.

Profiling leucocyte subsets in tuberculosis-diabetes co-morbidity.

Kumar NP, Moideen K, Dhakshinraj SD, Banurekha VV, Nair D, Dolla C, Kumaran P, Babu S.

Immunology. 2015 Oct;146(2):243-50. doi: 10.1111/imm.12496. Epub 2015 Jul 6.

18.

Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.

Ramachandran G, Kumar AK, Bhavani PK, Kannan T, Kumar SR, Gangadevi NP, Banurekha VV, Sekar L, Ravichandran N, Mathevan G, Sanjeeva GN, Dayal R, Swaminathan S.

Antimicrob Agents Chemother. 2015 Feb;59(2):1162-7. doi: 10.1128/AAC.04338-14. Epub 2014 Dec 8.

19.

Effect of 1,25-dihydroxy vitamin D3 on cathelicidin expression in patients with and without cavitary tuberculosis.

Afsal K, Harishankar M, Banurekha VV, Meenakshi N, Parthasarathy RT, Selvaraj P.

Tuberculosis (Edinb). 2014 Dec;94(6):599-605.

PMID:
25459161
20.

Coincident pre-diabetes is associated with dysregulated cytokine responses in pulmonary tuberculosis.

Kumar NP, Banurekha VV, Nair D, Sridhar R, Kornfeld H, Nutman TB, Babu S.

PLoS One. 2014 Nov 13;9(11):e112108. doi: 10.1371/journal.pone.0112108. eCollection 2014.

21.

Coincident helminth infection modulates systemic inflammation and immune activation in active pulmonary tuberculosis.

George PJ, Kumar NP, Sridhar R, Hanna LE, Nair D, Banurekha VV, Nutman TB, Babu S.

PLoS Negl Trop Dis. 2014 Nov 6;8(11):e3289. doi: 10.1371/journal.pntd.0003289. eCollection 2014.

22.

Type 2 diabetes mellitus is associated with altered CD8(+) T and natural killer cell function in pulmonary tuberculosis.

Kumar NP, Sridhar R, Nair D, Banurekha VV, Nutman TB, Babu S.

Immunology. 2015 Apr;144(4):677-86. doi: 10.1111/imm.12421.

23.

Decreased frequencies of circulating CD4⁺ T follicular helper cells associated with diminished plasma IL-21 in active pulmonary tuberculosis.

Kumar NP, Sridhar R, Hanna LE, Banurekha VV, Nutman TB, Babu S.

PLoS One. 2014 Oct 24;9(10):e111098. doi: 10.1371/journal.pone.0111098. eCollection 2014.

24.

Helminth infections coincident with active pulmonary tuberculosis inhibit mono- and multifunctional CD4+ and CD8+ T cell responses in a process dependent on IL-10.

George PJ, Anuradha R, Kumar NP, Sridhar R, Banurekha VV, Nutman TB, Babu S.

PLoS Pathog. 2014 Sep 11;10(9):e1004375. doi: 10.1371/journal.ppat.1004375. eCollection 2014 Sep.

25.

1,25-Dihydroxy vitamin D3 downregulates pro-inflammatory cytokine response in pulmonary tuberculosis.

Harishankar M, Afsal K, Banurekha VV, Meenakshi N, Selvaraj P.

Int Immunopharmacol. 2014 Nov;23(1):148-52. doi: 10.1016/j.intimp.2014.08.021. Epub 2014 Sep 4.

PMID:
25194676
26.

Altered CD8(+) T cell frequency and function in tuberculous lymphadenitis.

Kumar NP, Sridhar R, Hanna LE, Banurekha VV, Jawahar MS, Nutman TB, Babu S.

Tuberculosis (Edinb). 2014 Sep;94(5):482-93. doi: 10.1016/j.tube.2014.06.007. Epub 2014 Jul 1.

27.

Are we justified in treating for multidrug-resistant tuberculosis based on positive follow-up smear results?

Kumar RS, Kumar AM, Claassens M, Banurekha VV, Sekar G, Venkatesan P, Swaminathan S.

Int J Tuberc Lung Dis. 2014 Apr;18(4):449-53. doi: 10.5588/ijtld.13.0429.

PMID:
24670701
28.

Heightened plasma levels of heme oxygenase-1 and tissue inhibitor of metalloproteinase-4 as well as elevated peripheral neutrophil counts are associated with TB-diabetes comorbidity.

Andrade BB, Kumar NP, Sridhar R, Banurekha VV, Jawahar MS, Nutman TB, Sher A, Babu S.

Chest. 2014 Jun;145(6):1244-1254. doi: 10.1378/chest.13-1799.

29.

Number of sputum specimens during treatment follow-up of tuberculosis patients: two or one?

Kumar RS, Kumar AM, Claassens M, Banurekha VV, Gomathi NS, Venkatesan P, Swaminathan S.

Public Health Action. 2013 Dec 21;3(4):304-7. doi: 10.5588/pha.13.0049.

30.

Type 2 diabetes mellitus coincident with pulmonary tuberculosis is associated with heightened systemic type 1, type 17, and other proinflammatory cytokines.

Kumar NP, Sridhar R, Banurekha VV, Jawahar MS, Fay MP, Nutman TB, Babu S.

Ann Am Thorac Soc. 2013 Oct;10(5):441-9. doi: 10.1513/AnnalsATS.201305-112OC.

31.

Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.

Jawahar MS, Banurekha VV, Paramasivan CN, Rahman F, Ramachandran R, Venkatesan P, Balasubramanian R, Selvakumar N, Ponnuraja C, Iliayas AS, Gangadevi NP, Raman B, Baskaran D, Kumar SR, Kumar MM, Mohan V, Ganapathy S, Kumar V, Shanmugam G, Charles N, Sakthivel MR, Jagannath K, Chandrasekar C, Parthasarathy RT, Narayanan PR.

PLoS One. 2013 Jul 3;8(7):e67030. doi: 10.1371/journal.pone.0067030. Print 2013.

32.

Expansion of pathogen-specific T-helper 1 and T-helper 17 cells in pulmonary tuberculosis with coincident type 2 diabetes mellitus.

Kumar NP, Sridhar R, Banurekha VV, Jawahar MS, Nutman TB, Babu S.

J Infect Dis. 2013 Sep 1;208(5):739-48. doi: 10.1093/infdis/jit241. Epub 2013 May 28.

33.

IL-10 dependent suppression of type 1, type 2 and type 17 cytokines in active pulmonary tuberculosis.

Kumar NP, Gopinath V, Sridhar R, Hanna LE, Banurekha VV, Jawahar MS, Nutman TB, Babu S.

PLoS One. 2013;8(3):e59572. doi: 10.1371/journal.pone.0059572. Epub 2013 Mar 27.

34.

Expansion of pathogen-specific mono- and multifunctional Th1 and Th17 cells in multi-focal tuberculous lymphadenitis.

Kumar NP, Sridhar R, Banurekha VV, Nair D, Jawahar MS, Nutman TB, Babu S.

PLoS One. 2013;8(2):e57123. doi: 10.1371/journal.pone.0057123. Epub 2013 Feb 25.

35.

Effect of vitamin D3 on chemokine expression in pulmonary tuberculosis.

Selvaraj P, Harishankar M, Singh B, Banurekha VV, Jawahar MS.

Cytokine. 2012 Oct;60(1):212-9. doi: 10.1016/j.cyto.2012.06.238. Epub 2012 Jul 15.

PMID:
22800603
36.

Toll-like receptor and TIRAP gene polymorphisms in pulmonary tuberculosis patients of South India.

Selvaraj P, Harishankar M, Singh B, Jawahar MS, Banurekha VV.

Tuberculosis (Edinb). 2010 Sep;90(5):306-10. doi: 10.1016/j.tube.2010.08.001. Epub 2010 Aug 24.

PMID:
20797905
37.

Effect of vitamin D3 on phagocytic potential of macrophages with live Mycobacterium tuberculosis and lymphoproliferative response in pulmonary tuberculosis.

Chandra G, Selvaraj P, Jawahar MS, Banurekha VV, Narayanan PR.

J Clin Immunol. 2004 May;24(3):249-57.

PMID:
15114055

Supplemental Content

Loading ...
Support Center